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Lipidomics comparing DCD and 
DBD liver allografts uncovers 
lysophospholipids elevated in 
recipients undergoing early 
allograft dysfunction
Jin Xu1,*, Ana M. Casas-Ferreira1,3,*, Yun Ma2, Arundhuti Sen1, Min Kim1, Petroula Proitsi4, 
Maltina Shkodra1, Maria Tena1, Parthi Srinivasan2, Nigel Heaton2, Wayel Jassem2 & 
Cristina Legido-Quigley1
Finding specific biomarkers of liver damage in clinical evaluations could increase the pool of 
available organs for transplantation. Lipids are key regulators in cell necrosis and hence this study 
hypothesised that lipid levels could be altered in organs suffering severe ischemia. Matched pre- and 
post-transplant biopsies from donation after circulatory death (DCD, n = 36, mean warm ischemia 
time = 21min) and donation after brain death (DBD, n = 76, warm ischemia time = none) were 
collected. Lipidomic discovery and multivariate analysis (MVA) were applied. Afterwards, univariate 
analysis and clinical associations were conducted for selected lipids differentiating between these 
two groups. MVA grouped DCD vs. DBD (p = 6.20 × 10−12) and 12 phospholipids were selected for 
intact lipid measurements. Two lysophosphatidylcholines, LysoPC (16:0) and LysoPC (18:0), showed 
higher levels in DCD at pre-transplantation (q < 0.01). Lysophosphatidylcholines were associated with 
aspartate aminotransferase (AST) 14-day post-transplantation (q < 0.05) and were more abundant in 
recipients undergoing early allograft dysfunction (EAD) (p < 0.05). A receiver-operating characteristics 
(ROC) curve combining both lipid levels predicted EAD with 82% accuracy. These findings suggest 
that LysoPC (16:0) and LysoPC (18:0) might have a role in signalling liver tissue damage due to warm 
ischemia before transplantation.
Liver transplantation is the most viable solution to a range of acute and chronic end-stage liver diseases1. 
The global prevalence of liver disorders such as cirrhosis2, hepatitis B and C3,4 and non-alcoholic fatty 
liver disease5 have resulted in a marked increase in the demand for transplantation. However, widespread 
shortfalls in donor organ availability mean that the demand for transplantation greatly exceeds its actual 
occurrence1. This crippling donor shortage has led to the increase use of organs from ‘marginal’ donors6,7, 
including those obtained from donation after circulatory death (DCD). The use of DCD livers remains 
limited as organs are exposed to a significant period of warm ischemia prior to retrieval and have poorer 
patient outcomes8–10. It is estimated that up to a fifth of donation after brain death (DBD) organs do not 
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meet the strict clinical criteria for transplantation, and are thus discarded11, with higher losses reported 
for DCD grafts12. A primary goal of the pre-transplantation donor evaluation is determining whether the 
donor liver is more susceptible to graft dysfunction following transplantation13,14. While the assessment 
is an important patient safeguard, it may also result in otherwise transplantable organs being discarded. 
Increasing the pool of available and transplantable livers by identifying specific pre-transplantation mark-
ers of liver damage is thus a high priority15,16.
Elevated liver-enzyme levels are widely accepted as the standard for liver injury, however these tests 
lack specificity as they can be affected by medication and other syndromes17. Biomarker discovery in 
the context of liver pathophysiology has been predominantly genomic and transcriptomic-based18. In 
order to find metabolite markers in liver tissue, targeted and metabolite phenotyping strategies have 
been applied to find markers relevant to liver transplantation19,20, findings highlighted lipid associations 
to early allograft dysfunction (EAD) and recipient clinical outcomes14,21–23.
Here, we investigate lipid fingerprints at both pre- and post-transplantation, using ultra-performance 
liquid chromatography-mass spectrometry (UPLC-MS) in hepatic tissue in two distinct donor types: 
viz. DBD and DCD, the latter undergoing warm ischemia events24 . The main lipid differences between 
these two donor types were determined by an initial lipidomics screen (112 biopsies), which highlighted 
12 targeted phospholipids that were reanalysed in targeted mode and univariate comparisons. After this, 
associations to clinical outcomes were investigated. The study workflow is illustrated in Fig. 1.
Results
Clinical outcomes. There were no significant differences between DBD and DCD groups in donors’ 
ages, EAD/ immediate graft function (IGF) distribution, liver enzymes, hepatic steatosis or serum biliru-
bin levels. Differences were observed in the recipients’ ages (p < 0.01) between these two groups (Table 1).
Lipidomics multivariate analysis and selected phospholipids. To discover relevant lipid features, 
an orthogonal projections to latent structures-discriminant analysis (OPLS-DA) model (Supplementary 
Figure S1) among DBD and DCD grafts was built with n = 112. The model’s figures of merit were 
R2X = 0.659, R2Y = 0.941 and Q2 = 0.58. R2X explains a feature percentage (65.9%) which is explained 
by this model, R2Y indicates that 94.1% of the group variance is interpreted, and Q2 shows the predic-
tion ability of the model with 58%. 7-fold cross validation (CV) (CV p value = 6.20 × 10−12) suggested 
its reliability. From the model, 12 features differentiated among 2 groups with p[1]> 0.1, p(corr)> 0.4 & 
p[1]< − 0.05, p(corr)< − 0.18 were selected (Supplementary Table S1). These selected 12 features con-
sisted of 2 lysophosphatidylethanolamines (LysoPEs), 2 lysophosphatidylcholines (LysoPCs), 6 phos-
phatidylcholines (PCs) and 2 phosphatidyl-ethanolamines (PEs). Donor age, steatosis status, functional 
warm ischemia time (WIT) and cold ischemia time (CIT) showed low p[1] and p(corr) values and were 
not chosen as important variables. A heat map was computed to visualise trends for the 12 selected 
lipids (Fig. 2).
Targeted analysis of phospholipids per donor type during transplantation. From the heat 
map, no obvious differences were observed in the DBD group from pre- to post- for all 12 lipids except 
for PE (34:2). All lipids were more abundant in DCD at pre-transplantation stage compared with DBD. 
Figure 1. Study flowchart illustrates the overall design from untargeted analysis to semi-targeted 
analysis and association of potential biomarkers to clinical outcomes. DCD, donation after circulatory 
death; DBD, donation after brain death; OPLS-DA, orthogonal projections to latent structures-discriminant 
analysis; LysoPC, lysophosphatidylcholine; CIT, cold ischemia time; WIT, warm ischemia time, EAD, early 
allograft dysfunction; IGF, Immediate Graft Function; AST, aspartate aminotransferase.
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All 6 PCs levels remained constant from pre to post in the DCD group while 2 PEs, 2 LysoPEs and 2 
LysoPCs showed lower concentration at post- transplant stage.
12 lipids were reanalysed from the semi-quantified data for univariate analysis. The result of 
Mann-Whitney test with multiple comparison correction revealed that 2 lysophosphatidylcholines 
showed significant differences at pre transplantation stage (q = 0.002 and q = 0.003 respectively) between 
the two donor groups. Figure  3 shows the amounts for LysoPC (16:0) and LysoPC (18:0), Figs.  3a,b 
respectively show elevated levels in DCD when comparing to DBD for both LysoPCs (q < 0.01).
Correlation of selected lysophospholipids to clinical data. The distribution of 2 lysophosphati-
dylcholines in EAD (n = 15) and IGF (n = 41) groups was investigated. The Mann-Whitney test illus-
trated that the amount of LysoPC (16:0) and LysoPC (18:0) at pre-transplant were significantly higher 
in the EAD group (p = 0.013 and p = 0.03 respectively) (Fig.  4a,b). The prediction ability of LysoPCs 
(LysoPC (16:0) & LysoPC (18:0)) and clinical parameters (donor AST, donor age and steatosis status) was 
evaluated by receiver-operating characteristics (ROC) curve. The area under curve (AUC) for LysoPCs 
Donor DBD (N = 38) DCD (N=18) p-value[b]
Age (years) 53(25–82) 56(35–76) 0.494
Gender (female/male) 22/16 9/9 0.774
Hepatic steatosis
No 14 10
0.470Mild (< 30%) 18 6
Moderate (30–60%) 6 2
GGT (IU/L)[a] 54(6–208) 62(12–315) 0.686
AST (IU/L)[a] 85(22–517) 137(15–392) 0.281
Bilirubin (μ mol/L)[a] 11(3–37) 11(4–26) 0.845
ITU stay (days) 4(1–28) 3(1–10) NA
Inotrop support (Y/N) 22/16 11/7 1
Functional WIT (min)
NA
21(9–33)
NA
Hepatectomy time (min) 29(13–57)
Bench perfusion (min) 26(10–44)
Total WIT (min) 75(46–100)
CIT (min) 501(210–840) 430(84–720) 0.138
Recipient DBD (N = 38) DCD (N=18) p-value[b]
Age (years) 44(20–65) 55(46–70) 0.003
Gender (female/male) 17/21 6/12 0.563
BMI (kg/m2) 25.6(18.4–34.6) 26.5(15.9–35.8) 0.357
MELD Score (median) 13 13 NA
ALD 10 8
NA
PSC 6 0
HCV 1 4
HCC 1 2
BA 0 0
Others 20 4
AST (IU/L)[a] 1108(114–8075) 1968(309–10054) 0.075
Bilirubin day 7 (μ mol/L) 56(6–162) 65(12–175) 0.447
INR day 7 1.04(0.86–1.21) 1.15(0.92–1.96) 0.567
EAD/IGF 8/30 7/11 0.202
Table 1.  Summary of clinical data for liver donors and recipients. DBD, donation after brain death; 
DCD, donation after circulatory death; GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; 
ITU, intensive therapy unit; WIT, warm ischemia time; CIT, cold ischemia time; BMI, body mass index; 
MELD, model for end-stage liver disease; ALD, alcoholic liver disease; PSC, primary sclerosing cholangitis; 
HCV, hepatitis C virus; HCC, hepatocellular carcinoma; BA, biliary atresia; EAD, early allograft dysfunction; 
IGF, immediate graft function. Continuous values are expressed as means (minimum-maximum); NA, not 
applicable. Total WIT is the sum of Functional WIT, Hepatectomy time and Bench perfusion. aTested on the 
day of operation. bMann Whitney test (2-sided) or Fisher exact test (2-sided).
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group was 0.91 (accuracy = 0.82, sensitivity = 0.67, specificity = 0.86). For comparison, the AUC for 
three pre-transplant clinical parameters was 0.63 (accuracy = 0.68, sensitivity = 0.33, specificity = 0.77) 
(Fig. 4c).
The associations of the 2 selected pre-transplant lysophosphatidylcholines levels on biomedical param-
eters including AST, bilirubin, and creatinine levels within 14-day post-transplant were examined by 
mixed-effects maximum likelihood regression followed by Benjamini and Hochberg correction. Overall 
6 models were built with the combination of one biomedical parameter and one lipid in each model and 
adjusted for age and gender. Fitting was deemed adequate for all 6 models (p < 0.0001 from chi-square 
test). After multiple comparison correction, significant associations were observed between longitudi-
nal changes in AST concentration (slope) and LysoPC (16:0) levels (LysoPC (16:0) × day interaction 
(q < 0.05)), and between longitudinal changes in AST concentration (slope) and LysoPC (18:0) levels 
(LysoPC (18:0) × day interaction (q < 0.05)). For instance, with every standard deviation (SD) increase 
in LysoPC (16:0) × day interaction, recipients’ AST levels, on average, decreased 0.017 IU/L (with 95% 
confidence interval subscripts: LysoPC (16:0) × day interaction: -0.032− 0.017−0.003 p = 0.006). The model 
parameters are listed in Table 2 and the correlation between LysoPCs concentrations and the AST levels 
are present in Supplementary Figure S2.
Figure 2. Heat-map showing distinct lipid profiles of DBD and DCD tissue (n = 112). Values are median 
amounts per donor group at pre and post-transplantation stages. A clustering analysis (dendrogram) 
shows which lipids differ most; red depicts higher levels and blue means lower levels. DCD, donation after 
circulatory death; DBD, donation after brain death; PE, phosphatidylethanolamine; PC, phosphatidylcholine; 
LysoPC, lysophosphatidylcholine; LysoPE, lysophosphatidylethanolamine.
Figure 3. Bean-plots show levels for two lysophosphocholines (Mann-Whitney 2-sided, ** is q < 0.01, 
q value is p value adjusted by Benjamini and Hochberg FDR correction) among DCD and DBD at the 
pre-transplantation stage. (a) LysoPC (16:0); (b) LysoPC (18:0). DCD, donation after circulatory death; 
DBD, donation after brain death; LysoPC, lysophosphatidylcholine.
www.nature.com/scientificreports/
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Discussion
The urgent need for specific molecular markers of hepatic tissue quality has given rise to small molecule 
phenotyping studies investigating a range of liver pathologies14,25. The study reported here is the first 
study to distinguish lipid profiles between two different liver-donor types, with correlations to clini-
cal outcomes related with liver graft dysfunction and clinical follow-up. Matched liver tissue biopsies 
were obtained at both pre- and post-transplantation stages from two types of donors, viz. DBD and 
DCD. DBD livers may suffer inflammatory changes in relation to brain death and ITU management, and 
undergo a significant period of cold preservation following retrieval. DCD donors have no diagnosis of 
brain death; however, livers from DCD undergo an additional period of warm ischemia prior to retrieval. 
Figure 4. Two LysoPCs amounts, (a) LysoPC (16:0) and (b) LysoPC (18:0), showing significant 
differences between EAD (n = 15) and IGF (n = 41) groups (Mann-Whitney 2-sided, is *p < 0.05); 
(c) ROC curve prediction of EAD based on two LysoPCs and three donor clinical parameters. LysoPC, 
lysophosphatidylcholine; EAD, early allograft dysfunction; IGF, immediate graft function; ROC, receiver 
operating characteristic.
AST Coefficient
95% confidence 
interval p-value
Model 1
LysoPC (16:0) 0.122 − 0.068, 0.313 0.21
day − 0.0003 − 0.016, 0.015 0.97
LysoPC(16:0) × day − 0.017 − 0.032, − 0.003 0.006
Model 2
LysoPC (18:0) 0.117 − 0.073, − 0.308 0.229
day − 0.0003 − 0.016, 0.015 0.965
LysoPC(18:0) × day − 0.02 − 0.035, − 0.005 0.007
Table 2.  Mixed-effect models summarizing the baseline and longitudinal associations between LysoPC 
levels and AST concentration. LysoPC(16:0) and LysoPC(18:0) indicated baseline associations (intercept) 
and the interaction with day indicates longitudinal associations (slope). LysoPC, Lysophosphatidylcholine; 
AST, aspartate aminotransferase.
www.nature.com/scientificreports/
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This ischemia period has been previously associated with increased rates of graft failure and with both 
short and long-term complications following transplantation10. A substantial number of DCD organs are 
thus discarded because of the lack of precise assays to evaluate transplant outcomes.
Inflammatory responses in donor liver biopsies are donor-type specific, DBD tissue showed high 
levels of pro-inflammatory changes at the pre-transplantation stage. This was attributed to inflammatory 
events associated with brain death in the donors26. Following reperfusion, DBD tissue showed high 
levels of neutrophil infiltration and deposition of activated platelets. On the other hand, DCD allografts 
demonstrated lower inflammatory response but higher cell death rates that correlated with the length 
of warm ischemia26,27. Since increasing cell death was observed in DCD, we hypothesised that lipid cell 
death mediators could be affected during transplant28.
By focusing on donor-type using lipidomics for discovery, we identified 12 lipids differentiating 
among DBD and DCD. Trends were illustrated in the heat-map (Fig. 2) for the lipid median values in 
pre- and post- transplantation across the two donor types. This panel of lipids did not change from pre- 
to post-transplant in the same donor type, implying that lipid changes observed at pre-transplantation 
are likely to be related to ischemia damage rather than reperfusion injury.
PCs were more abundant in DCD at both transplant stages. Phosphatidylcholines have been associ-
ated with inflammation29. However, contradictory data shows that these lipids could have a protective 
function as studies have linked them to regeneration processes in the liver30–32.
Twelve lipids were measured again and univariate analysis was applied. Lipids with statistical signif-
icance when comparing DBD and DCD in both pre- and post-transplant biopsies were LysoPC (16:0) 
(q < 0.01) and LysoPC (18:0) (q < 0.01) showing higher values in DCD (Fig. 3).
LysoPCs are lysophospholipids generated from PCs (Fig. 5) via the action of phospholipase A2, and 
like other lysophospholipids they are likely to be activators or inhibitors of G-protein coupled receptors 
(GPCRs)33. Phospholipase A2 synthesises lysophospholipids including both lysoPCs and lysoPEs from 
PEs and PCs by producing free fatty acids.
In DCD donors, LysoPCs were found to be increased. LysoPCs are known to be precursors of the 
platelet-activating factor (PAF), a potent phospholipid inflammatory, which has been previously associ-
ated with both hepatic ischemia and reperfusion injury (IRI)34–36. Hence, DCD donors might be prone 
to the PAF mediated inflammatory pathway before transplantation (pathway illustrated in Fig. 5).
The in-vivo function of LysoPCs and in particular their role in intracellular signalling is mostly 
unknown. LysoPCs have previously been associated with inflammatory liver disease37,38. Interestingly 
Cortes et al.14 found in a study of liver transplantation with DBD grafts that LysoPC (16:0) and LysoPC 
(18:0) were higher in grafts that presented EAD p < 0.05, supporting the hypothesis that these lysophos-
pholipids affect transplant outcomes.
To understand the relevance of the two lipids to transplantation we investigated EAD. EAD is a 
clinical term which can reflect donor, recipient and transplant characteristics, and it can be utilized as 
a transplant benchmark39. The incidence of EAD in our study was 26%, this was in the upper range 
of known values for incidence ranging from 14% to 27%40. LysoPC (16:0) and LysoPC (18:0) showed 
(p < 0.05) significant difference when their contents between EAD and IGF groups were compared. The 
ROC curve of these two LysoPCs versus three clinical parameters known to be risk factors of EAD 
indicated that LysoPC (16:0) and LysoPC (18:0) were better at prediction of EAD, in particular accuracy 
increased from 68% for AST, age and steatosis to 82% for LysoPCs. A limitation of this comparison is that 
it was applied to compare donors only at pre-transplantation; however it is known that EAD is affected 
by multiple factors including the recipients and the surgery procedures41.
The regression between AST 14-day concentrations and two LysoPCs indicated that LysoPCs levels at 
pre-transplant were associated to AST concentration at post-transplant. The model indicated LysoPCs’ 
association with higher AST immediately after transplant. Since AST is considered an indicator of liver 
injury, the association between high AST post-transplantation and LysoPCs pre-transplantation warrants 
further investigation of LysoPC (16:0) and LysoPC (18:0) as markers of liver damage.
In conclusion, the analysis of phospholipids in the context of liver transplantation has identified two 
lipids differentiated in DBD and DCD livers. LysoPC (16:0) and LysoPC (18:0) could have a role as 
intermediates in signalling tissue damage due to warm ischemia. This study is relevant in identifying 
pre-transplant biomarkers for tissue quality and in designing appropriate therapeutic strategies in order 
to minimize damage related to ischemia injury.
Patients and Methods
Patients and biopsy collection. This study received prior approval from the ethics committee at 
King’s College Hospital, and informed consent was obtained from all subjects. The methods were carried 
out in accordance with the approved guidelines. Overall 112 Tru-Cut tissue biopsies were obtained from 
liver allografts pre- and post-transplantation. The first (pre-transplant) biopsy was taken at the end of 
cold preservation, prior to implantation, and the second (post-transplant) biopsy was obtained approx-
imately 1 hour after graft reperfusion. A separate biopsy was obtained for histopathological evaluation 
of donor steatosis. Biopsies were immediately snap-frozen in liquid nitrogen and stored at –80°C until 
extraction for LC-MS analysis. In all procedures, liver allografts were flash-cooled and perfused with 
University of Wisconsin preservation fluids until the time of transplantation.
www.nature.com/scientificreports/
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Power calculations were performed for DBD (n = 38) and DCD (n = 18) participants using 
“Gpower3.1” (http://www.gpower.hhu.de/). Assuming a two-sided Type I error of 0.05 and standard 
normal distributions for lipid molecules, this study has > 80% power to detect differences between two 
groups based on our previous work21.
Donors. The study included two types of adult donors: DBD (n = 38) and DCD (n = 18). A wide 
spectrum of donor clinical data was collected for comparison among groups and for correlation with 
lipid levels. In the DBD group, 18 of the livers had mild steatosis (up to 30% fat on biopsies), 6 had 
moderate steatosis (30–60% fat) and the remaining DBD grafts had none. In the DCD group, 2 allografts 
were mildly steatotic, 6 allografts were moderately steatotic and the remainder were normal. In the DCD 
group, WIT was calculated from the time when systolic blood pressure was below 50 mmHg to the time 
of cold perfusion. Total WIT is the sum of Functional WIT, Hepatectomy time and Bench perfusion. The 
relevant donor data are included in Table 1.
IGF. Recipients. All recipients were patients with stable chronic liver disease who did not require 
hospitalization prior to transplantation. Indications of liver transplantation in the study include alcoholic 
Figure 5. Lipid metabolism in the healthy liver, showing endogenous metabolism of triacylglycerol 
(TAG) and phospholipids. Phosphatidic acid (PA) is generated in vivo by catabolic modification of 
glycerol-3-phosphate. Diacyglycerol (DAG) is a key metabolic intermediate and intracellular signalling 
molecule which can be converted to TAGs by the action of DAG acyltransferases to glycerophospholipids 
including phosphatidylcholines (PC), phosphatidylethanolamines (PE) and ultimately to lysophosphatidylcholines 
(LysoPC), lysophosphatidylethanolamines (LysoPE) by the action of phospholipase A2. LysoPCs showed 
higher amounts in donation after circulatory death (DCD) group in this study.
www.nature.com/scientificreports/
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liver disease (ALD), primary sclerosing cholangitis (PSC), hepatitis C virus (HCV), hepatocellular car-
cinoma (HCC), biliary atresia (BA) and others. After transplantation, all patients received immunosup-
pressive therapy with tacrolimus and prednisolone. Recipients’ 14-day period of international normalized 
ratio (INR), AST, albumin, gamma-glutamyl transferase (GGT), bilirubin, alkaline phosphatase (ALP) 
and creatinine were recorded. Graft performance was assessed based on AST, INR and bilirubin levels 
after transplantation42. According to graft performance, recipients were classified into two groups: show-
ing EAD (n = 15) and IGF (n = 41). The relevant recipient details are listed in Table 1.
Lipidomics. Sample preparation for all 112 biopsies and lipidomic analysis followed our previously 
published method43. Lipidomics was performed using Waters ACQUITY ultra-performance liquid 
chromatography-quadrupole time of flight (UPLC-QToF) in both positive and negative ionisation mode. 
All data was processed within XCMS in R and exported into SIMCA version 13 (MKS Umetrics AB, 
Sweden) for multivariate analysis. Multivariate analysis included pre- and post-transplant matched sam-
ples n = 112 (DBD n = 76, DCD n = 36). Donor age, steatosis status, WIT and CIT were included as 
X-variables for multivariate analysis. OPLS-DA was then performed to select features based on covari-
ance p[1] and correlation p(corr) value (p[1]> 0.1, p(corr)> 0.4 & p[1]< -0.05, p(corr)< -0.18).
Intact Lipid Analysis. Selected lipids were measured in the LC-MS data using Waters MassLynx software 
(Waters Corporation, Milford, MA) and peak areas were normalized to total ion count ratios. The iden-
tification was performed by structure and fragmentation patterns in the MS2 data44–46. Supplementary 
Table S1 contains the relevant analytical data for the lipid panel analysis (list of mass-to-charge ratio 
or m/z values, the observed ions and the instrumental variation of the measurements in QC samples).
Median values were used to plot the heat-map using an open source ‘R’ with ‘gplots’ package47, 
bean-plots were drawn in ‘beanplot’ package48. Levels in each group at pre- and post-transplantation 
stage as well as between DCD and DBD groups were examined with univariate non-parametric 
Mann-Whitney test (2-sided) with Benjamini and Hochberg correction to control for false discovery49. 
All p values were represented as q values after correction. Lipids with q < 0.01 were selected for clinical 
correlation analysis.
Clinical correlations. The selected lipid levels in both EAD and IGF groups were investigated with 
Mann-Whitney test (2-sided) to examine any lipid distribution differences, calculations were conducted 
in SPSS 22 (IBM: Armonk, United States). A prediction model in regard to EAD was built using ROC 
curve for two combined LysoPCs (LysoPC (16:0) & LysoPC (18:0)) and three combined clinical data 
(donor AST, donor age and steatosis status) in ‘R’ with ‘pROC’ package. The prediction ability of these 
two curves was assessed by area under curve, accuracy, sensitivity and specificity.
Mixed linear mixed effects models were used to investigate the longitudinal associations between 
recipients’ 14-day AST, bilirubin and creatinine concentrations and each lipid pre-transplant levels. Data 
were scaled to obtain standard deviation of 1. The average baseline AST, bilirubin and creatinine con-
centrations and the average change in their concentrations over 14 days (follow-up time) were calculated 
for all subjects per visit (day) as a group (fixed effects) and subject-specific intercept and slope terms, 
which reflected deviation from the group average (mixed linear effects) were calculated. An interaction 
term between visit (day) and lipid pre-transplant levels was used to investigate whether the recipients’ 
longitudinal AST, bilirubin and creatinine concentrations (slope) was associated with lipid pre-transplant 
levels. All calculations included adjustment for age and gender for the 56 donors. All obtained p values 
were corrected for multiple comparisons and results given as q values. Linear mixed effect models were 
performed in Stata/SE13 (StataCorp: Texas, United States).
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